These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12412791)

  • 1. Calcimimetics in the treatment of primary hyperparathyroidism.
    Antoniucci DM; Shoback D
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N141-5. PubMed ID: 12412791
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcimimetics: therapeutic potential in hyperparathyroidism.
    Cohen A; Silverberg SJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):734-9. PubMed ID: 12482739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetic agents and the calcium-sensing receptor.
    Coburn JW; Maung HM
    Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcium receptor and calcimimetics.
    Wada M; Nagano N; Nemeth EF
    Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcium receptor/calcium-sensing receptor].
    Nagano N
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):188-90. PubMed ID: 17139821
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
    Negri AL; Slatopolsky EA
    Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future role of calcimimetics in end-stage renal disease.
    Goodman WG; Turner SA
    Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.
    Lu JY; Yang Y; Gnacadja G; Christopoulos A; Reagan JD
    J Pharmacol Exp Ther; 2009 Dec; 331(3):775-86. PubMed ID: 19759318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
    Rybczyńska A; Hoppe A
    Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.
    Silverberg SJ; Bone HG; Marriott TB; Locker FG; Thys-Jacobs S; Dziem G; Kaatz S; Sanguinetti EL; Bilezikian JP
    N Engl J Med; 1997 Nov; 337(21):1506-10. PubMed ID: 9366582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
    Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new role of calcimimetics as vasculotropic agents.
    Al-Aly Z
    Kidney Int; 2009 Jan; 75(1):9-12. PubMed ID: 19092812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathology and therapy of primary hyperparathyroidism].
    Sugimoto T
    Nihon Naika Gakkai Zasshi; 1999 Jul; 88(7):1206-11. PubMed ID: 10465965
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium-sensing receptor and calcimimetic agents.
    Coburn JW; Elangovan L; Goodman WG; Frazaõ JM
    Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcimimetic inhibits late-stage cyst growth in ADPKD.
    Gattone VH; Chen NX; Sinders RM; Seifert MF; Duan D; Martin D; Henley C; Moe SM
    J Am Soc Nephrol; 2009 Jul; 20(7):1527-32. PubMed ID: 19423689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.